Php217 - Time to Market and Price Comparison for Biosimilar Drugs in Eu5

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.1111
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Time to Reimbursement for Oncology Drugs in EU5

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Market Approval for Drugs in the EU: Time to Change Direction?

European Journal of Health Economics
Health PolicyEconomicsEconometricsFinance
2016English

Cross-National Comparison of Biosimilar Medicines : Market Penetration and Competition With Originators

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Price Comparison of New Drugs in Japan, Eu and Us

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

First Biosimilar Drug Set to Enter US Market

Nature
Multidisciplinary
2015English

Patents, Price Controls and Access to New Drugs: How Policy Affects Global Market Entry

SSRN Electronic Journal
2008English

Psy169 - Comparison of Eu5 Market Access Decisions for Crohn’s Disease Based on the Prismaccess® Database

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Php230 - Eu5 Market Access for Medicines Approved Under Exceptional Circumstances

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Php229 - Eu5 Market Access for Medicines With Conditional Marketing Authorisations

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy